Ultivue Announces Co-Marketing Agreement with Fluidigm for Biomarker Imaging Solutions for Precision Medicine
5.8.2021 16:30:00 EEST | Business Wire | Press release
Ultivue, Inc. and Fluidigm Corporation (Nasdaq:FLDM) today announced a co-marketing agreement in which the companies will offer customers a comprehensive portfolio of workflow solutions for biomarker discovery and drug development.
Ultivue, a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation develops unique assays for use in multiplex immunofluorescence imaging and analysis. Its proprietary InSituPlex® technology is designed for fast and comprehensive exploration of biologically-relevant markers combined with same slide-H&E analysis in precious tissue samples.
Fluidigm is a leader in high-parameter imaging for the clinical translational research and clinical testing markets. It’s Imaging Mass Cytometry™ (IMC™) technology is designed for highly multiplexed targeted interrogation of tissue sections for 40 or more protein markers in one scan, with distinct non-overlapping signals from element-labeled antibodies detected simultaneously for each sub-micrometer pixel.
The collaboration provides reseachers with end-to-end service capability for clinical and translational work. For example, InSituPlex technology is well suited to identify regions of interest that may require downstream, deep profiling with IMC™. Customer access to both technologies can improve the efficiency of drug discovery programs and, in translational research, enable patient stratification to triage cases that require further investigation.
“Imaging Mass Cytometry has become integral to the clinical translational research and clinical testing markets,” said Chris Linthwaite, Fluidigm President and CEO. “Through Fluidigm Therapeutic Insights Services, we will offer our customers access to our technology as well as that of Ultivue, providing optimum imaging solutions for biomarker discovery and drug development.”
“Ultivue is at the forefront of innovation to provide unique biological insights for our customers,” said Mark Rees, Vice-President of Business Development at Ultivue. “Our InSituPlex® technology offers valuable profiling of the tissue and expands the depth of information possible from a single section that is complementary to the high-parameter capabilities of Imaging Mass Cytometry. We believe this joint offering with Fluidigm will now provide researchers a seamless workflow enabling a far more efficient biomarker discovery and drug development process.”
About Fluidigm
Fluidigm Corporation (Nasdaq:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, we strive to increase the quality of life for all.
Fluidigm, the Fluidigm logo, and CyTOF are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners. For Research Use Only. Not for use in diagnostic procedures. For more information, visit fluidigm.com.
About Ultivue
Ultivue, Inc. provides researchers and scientists with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex® technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions and scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. For more information, visit ultivue.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210805005443/en/
Contact information
Ultivue
Mark Rees, PhD
Vice President Corporate Development
(+1) 516-512-4977
mark.rees@ultivue.com
Fluidigm
Mark Spearman
Senior Director, Corporate Communications
(+1) 650-243-6621
mark.spearman@fluidigm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nine in 10 Firms Fear In-House Systems Can’t Keep Pace with Executive Pay Demands19.5.2026 16:00:00 EEST | Press release
Managing executive compensation is a growing challenge for financial services firms, with nearly nine in 10 (89%) saying their in-house technology can’t keep pace with demand. New research by CSC, the leading provider of business administration and compliance solutions, shows that rising complexity, regulatory pressure, and expanding global participation place increasing strain on internal systems and teams.1 CSC surveyed 300 senior HR, rewards, and compensation leaders across Europe, Asia Pacific, and North America working in private markets, asset management, insurance, and investment banking. The report, The Future of Reward in Financial Services: Executive Compensation in 2026, explores their responses and examines how firms adapt to increasing complexity in long-term incentive (LTI) schemes. The research revealed that more than four in five (86%) respondents find the administration of compensation schemes is now complex, reflecting the rapid evolution and expansion of LTI structur
Tacton Appoints Manufacturing Technology Leader Mike DiTullio to Board of Directors19.5.2026 16:00:00 EEST | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) solutions for manufacturers of complex products, today announced the appointment of Mike DiTullio to its Board of Directors. DiTullio is an enterprise software executive with more than three decades of experience working with complex manufacturers. He joins at a pivotal moment in the company’s evolution as Tacton expands beyond CPQ to deliver the Buyer-Centric Smart Factory, a connected approach that unites buyer engagement, engineering, and order fulfillment into a single intelligent system. DiTullio spent 26 years at PTC, most recently as President and Chief Operating Officer, wherehe worked closely with leading manufacturers to transform how they design, sell, and deliver complex products. In that role, he led global commercial operations across seven business units representing more than $1.5 billion in annual revenue and guided the company through its transition to a subscription-based, digital-first business model. His deep
Echodyne and Moog Successfully Demonstrate Reconfigurable Integrated-weapon Platform (RIwP®) at U.S. Army Exercise19.5.2026 16:00:00 EEST | Press release
Echodyne, the radar platform company, and Moog Inc. (NYSE: MOG.A and MOG.B), a worldwide designer, manufacturer, and systems integrator of high performance precision motion and control systems, announce the results of testing of their defensive systems to counter small offensive UAS (“sUAS”) weapons. Capabilities Tested Live detection, lock on with precision tracking, and successfully engaging of Group 1-3 UAS threats in less than 3 seconds. Combined AI targeting, wireless fire control, and radar integration across mission equipment capabilities for defense against small UAS weapons. AI targeting for passive detection, autonomous targeting, track re-acquire, multi-object targeting. Outputs Identified and swiftly rectified critical capability gaps within a simulated battlefield environment. Proved that combining precision data with AI firing solution computation is a cost-effective solution for rapidly upgrading existing kinetic weapon stations to highly effective C-UAS systems. One of
Torq Acquires Jit to Unleash the First Enterprise AI SOC Context Graph—and Rewrite the Future of SecOps19.5.2026 16:00:00 EEST | Press release
Torq, the established agentic security operations leader, today announced the acquisition of Jit, the Boston-based AI Context Graph cybersecurity pioneer. This move marks a dramatic leap forward for the Torq AI SOC Platform by ensuring agentic investigations are precisely informed via organization-specific contextual data. This shift redefines agentic reasoning, moving beyond static facts such as users, devices and their relationships, to prioritize live, dynamic contextual data overlaid on top, including business drivers, and the real-time state of the enterprise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519044833/en/ Instead of acting on fragmented data or having investigations triggered by a single alert, Torq AI operates with a unified, continuously-updated, contextual inference, enabling decisions that are not only explainable, but inherently grounded in a single and up-to-date source of truth. This reflects no
Cohere Acquires Reliant AI to Expand Sovereign Enterprise AI for the Global Biopharma and Healthcare Sectors19.5.2026 16:00:00 EEST | Press release
Cohere, the world’s leading sovereign AI company, announced today the acquisition of Reliant AI, a leading biopharma AI company with operations in Montreal and Berlin. This acquisition brings Reliant AI’s world-class research team, proprietary biomedical datasets, and domain-optimized technology into Cohere’s enterprise-grade sovereign AI platform. This significantly expands Cohere’s footprint in the global healthcare and life sciences sectors–where security, data privacy, and regulatory compliance are paramount—and builds on Cohere’s existing partnerships across administrative, clinical, and revenue cycle workflows. The acquisition strengthens Cohere’s position as global sovereign AI leader, building on its established presence in Canada and Germany and growing momentum across Europe. Together, Cohere and Reliant AI will equip healthcare and life sciences enterprises with a powerful combination of cutting-edge AI technology, secure deployment options for highly regulated environments,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom